Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials

Steven J Skates; Mark H Greene; Saundra S Buys; Phuong L Mai; Powel Brown; Marion Piedmonte; Gustavo Rodriguez; John O Schorge; Mark Sherman; Mary B Daly; Thomas Rutherford; Wendy R Brewster; David M O'Malley; Edward Partridge; John Boggess; Charles W Drescher; Claudine Isaacs; Andrew Berchuck; Susan Domchek; Susan A Davidson; Robert Edwards; Steven A Elg; Katie Wakeley; Kelly-Anne Phillips; Deborah Armstrong; Ira Horowitz; Carol J Fabian; Joan Walker; Patrick M Sluss; William Welch; Lori Minasian; Nora K Horick; Carol H Kasten; Susan Nayfield; David Alberts; Dianne M Finkelstein; Karen H Lu

Journal article

Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials

Steven J Skates, Mark H Greene, Saundra S Buys, Phuong L Mai, Powel Brown, Marion Piedmonte, Gustavo Rodriguez, John O Schorge, Mark Sherman, Mary B Daly, Thomas Rutherford, Wendy R Brewster, David M O'Malley, Edward Partridge, John Boggess, Charles W Drescher, Claudine Isaacs, Andrew Berchuck, Susan Domchek, Susan A Davidson Show all

Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2017

DOI: 10.1158/1078-0432.CCR-15-2750

University of Melbourne Researchers

Kelly Phillips Author The Sir Peter MacCallum Department of Oncology

Grants

Awarded by Early Detection Research Network

Awarded by Clinical Genetics Branch

Awarded by National Cancer Institute

Awarded by GOG Statistical and Data Center

Awarded by NCI's Community Clinical Oncology Program (CCOP) grant

Awarded by National Breast Cancer Foundation

Awarded by NATIONAL CANCER INSTITUTE

Funding Acknowledgements

The ROCA study was supported mainly by research grants/contracts from NCI to sites in the Cancer Genetics Network, the Ovarian SPORE program, and the Early Detection Research Network (CA078284 to D.M. Finkelstein, CA078134 to H. Anton-Culver, CA078164 to D. Bowen, CA078156 to S. Domchek, CA078148 to C. Griffin, CA078146 to C. Isaacs, CA078174 to G. Mineau, CA078157 to J. Schildkraut, CA078142 to L. Strong, HHSN2612007440000C to D.M. Finkelstein, CA083638 to R. Ozols, CA083591 to E. Partridge, CA086389 to H. Lynch). Fujirebio Diagnostics Inc supported the CGN study for one year after NCI funding ended. P.L. Mai and M. H. Greene were supported by the Intramural Research Program, NCI/NIH. The Gynecologic Oncology Group's study (GOG-0199) was supported by intramural research funds from the Clinical Genetics Branch and National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office and Tissue Bank (CA027469 to P. Di Saia), the GOG Statistical and Data Center (CA037517 to J. Blessing), and by NCI's Community Clinical Oncology Program (CCOP) grant (CA101165 to P. Di Saia). Participation by the investigators of the Australia and New Zealand Gynaecological Oncology Group (ANZGOG) is gratefully acknowledged. K.-A. Phillips is an Australian National Breast Cancer Foundation Fellow.